Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 54

Sort by

Sort Order Select

Journal Articles

T rial of Imatinib after Ponatinib Induction (TIPI) in the Front-Line Treatment of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Setting. Report of the First Therapeutic Sequence

Blood (2023) 142 (Supplement 1): 445.

https://doi.org/10.1182/blood-2023-181571

Published: 2023

Journal Articles

Correlation of Clonal Hematopoiesis in Vexas Syndrome with Immunophenotype Alterations in CD34+ HSPCs (Hematopoietic Stem Progenitors Cells): Multiparametric Flow Cytometry Heterogeneity in CD34+CD38- Stem Cells Fraction and Upregulation of CD90 Thy-1 By Unsupervised Strategy Using PCA, Tsnee and Flowsom

Adriana Plesa, Joris Gutrin, Christophe Roumier, Sandrine Hayette, Isabelle Tigaud, Sarah Huet, Delphine Manzoni, Florent Dumezy, Fiorenza Barraco, Herve Ghesquieres, Claude Preudhomme, Pierre Sujobert, Mael Heiblig

Blood (2022) 140 (Supplement 1): 4086–4087.

https://doi.org/10.1182/blood-2022-169959

Published: 2022

Journal Articles

Therapy-Related Acute Myeloid Leukemia (t-AML) and the Advantage of Intensive Chemotherapy: Real-Life Analysis from Two Regional French Centers

Blood (2021) 138 (Supplement 1): 4379.

https://doi.org/10.1182/blood-2021-148678

Published: 2021

Journal Articles

Characteristics and Outcomes of Therapy-Related Acute Myeloid Leukemia: Results of Retrospective Analysis of 116 Adult Patients

Amine Belhabri, MD, Liliana Vila, MD, Mael Heiblig, Stephane Morisset, BioStat, Emmanuelle Nicolas-Virelizier, MD, Clémence Santana, MD, Isabelle Tigaud, MD, Sandrine Hayette, PhD, Anne-Sophie Michallet, MD PhD, Philippe Rey, MD, Yann Guillermin, MD, Souad Assad, MD, Laure Lebras, MD, Mauricette Michallet, MD PhD

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-142956

Published: 2020

Journal Articles

Stemness Signature in AML: GEP with 17 Genes Score Versus Leukemic Stem Cell (LSC) Quantification By Multiparameter Flow Cytometry (MFC)

Adriana Plesa, Christophe Roumier, PharmD, Florent Dumezy, PharmD, Delphine Manzoni, PharmD, Pierre Sujobert, MD PhD, Sandrine Hayette, Isabelle Tigaud, MD, Claude Preudhomme, Karine Celli-Lebras, CRA, Yves Bertrand, MD, Herve Dombret, Xavier Thomas, MD, Meyling Cheok, BSPharm, PhD

Blood (2018) 132 (Supplement 1): 4009.

https://doi.org/10.1182/blood-2018-99-119857

Published: 2018

Journal Articles

CP-CML Seems Related to Specific HLA Subtypes and the HLA DRB1 07 Allele Might Identify a Subgroup of Newly Diagnosed CP-CML Patients on Imatinib First-Line of Better Prognosis

Franck-Emmanuel Nicolini, MD PhD, Stéphanie Désilets, MD, Sandrine Hayette, PhD, Isabelle Tigaud, MD, Liliana Vila, Stephane Morisset, Stat, Mohamad Sobh, PharmD, Mauricette Michallet, MD PhD, Valerie Dubois, MD

Blood (2018) 132 (Supplement 1): 5436.

https://doi.org/10.1182/blood-2018-99-117733

Published: 2018

Journal Articles

Deep Molecular Response in Imatinib First-Line 418 Newly Diagnosed CP CML Patients.

Franck Emmanuel Nicolini, MD PhD, Vincent Alcazer, MD, Pascale Cony-Makhoul, MD PhD, Stephanie Dulucq, PhD, Sandrine Hayette, PhD, Isabelle Tigaud, MD, Liliana Villa, MD, Mohamad Sobh, PharmD, Stephane Morisset, Stat, Francois-Xavier Mahon, MD PhD, Gabriel Etienne, MD PhD

Blood (2018) 132 (Supplement 1): 3014.

https://doi.org/10.1182/blood-2018-99-113044

Published: 2018

Journal Articles

Validation of the prognostic value of the knowledge bank approach to determine AML prognosis in real life

Sarah Huet, Etienne Paubelle, Camille Lours, Beatrice Grange, Lucien Courtois, Kaddour Chabane, Carole Charlot, Isabelle Mosnier, Thomas Simonet, Sandrine Hayette, Isabelle Tigaud, Xavier Thomas, Gilles Salles, Fabien Subtil, Pierre Sujobert

Blood (2018) 132 (8): 865–867.

https://doi.org/10.1182/blood-2018-03-840348

Published: 2018

Includes: Supplemental data

Journal Articles

B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) with t(5;14)(q31;q32)/ IL3-IGH Rearrangement and Eosinophilia: A Peculiar IGH BCP-ALL

Blood (2017) 130 (Supplement 1): 2572.

https://doi.org/10.1182/blood.V130.Suppl_1.2572.2572

Published: 2017

Journal Articles

Impact of Body Mass Index on Outcome in Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with Imatinib in First-Line

Gaelle Fossard, MD, Vincent Alcazer, MD, Marie Balsat, MD, Helene Labussiere-Wallet, MD, Stephane Morisset, Stat, Mohamad Sobh, Isabelle Tigaud, MD, Pierre Sujobert, MD PhD, Mauricette Michallet, MD PhD, Franck Emmanuel Nicolini, MD PhD

Blood (2017) 130 (Supplement 1): 2900.

https://doi.org/10.1182/blood.V130.Suppl_1.2900.2900

Published: 2017

Journal Articles

Impact of cytogenetic abnormalities in adults with Ph-negative B-cell precursor acute lymphoblastic leukemia

Blood (2017) 130 (16): 1832–1844.

https://doi.org/10.1182/blood-2017-05-783852

Published: 2017

Includes: Supplemental data

Journal Articles

Comprehensive analysis of a myeloperoxidase-negative acute promyelocytic leukemia

Maël Heiblig, Etienne Paubelle, Adriana Plesa, Marie-Oldine Geay, Delphine Manzoni, Sophie Gazzo, Isabelle Tigaud, Evelyne Callet-Bauchu, Sarah Huet, Gilles Salles, Xavier Thomas, Sandrine Hayette, Pierre Sujobert

Blood (2017) 129 (1): 128–131.

https://doi.org/10.1182/blood-2016-09-741355

Published: 2017

Journal Articles

Very Long-Term Follow-up (> 80 months) of Imatinib (IM) First-Line for Chronic Phase (CP) CML Patients

Franck E. Nicolini, MD PhD, Marie Balsat, MD, Maud Lekieffre, MD, Vincent Alcazer, MD, Hélène Labussière-wallet, MD, Sarah Huet, PharmD, PhD, Sandrine Hayette, Stéphanie Dulucq, PharmD, PhD, Stéphane Morisset, Stat, Jeremy Ruby, CRA, Isabelle Tigaud, MD, Marie-Pierre Fort, CRA, Mael Heiblig, MD, Rémi Chapelon, CRA, Madeleine Etienne, CRA, Mohamad Sobh, PharmD, Francois-Xavier Mahon, MD PhD Professor, Mauricette Michallet, MD PhD, Gabriel Etienne, MD PhD

Blood (2015) 126 (23): 2774.

https://doi.org/10.1182/blood.V126.23.2774.2774

Published: 2015

Journal Articles

Value of Cytogenetic Abnormalities in Adult Patients with Philadelphia Chromosome (Ph)-Negative Acute Lymphoblastic Leukemia (ALL) Treated in the Pediatric-Inspired Trials from the Group for Research on Adult ALL (GRAALL)

Blood (2014) 124 (21): 492.

https://doi.org/10.1182/blood.V124.21.492.492

Published: 2014

Journal Articles

Flamsa Sequential Chemotherapy Followed By Reduced Intensity Conditioning and Allogeneic Hematopoietic Transplantation for High Risk Acute Myeloid Leukemia Patients

Mauricette Michallet, MD PhD, Mohamad Sobh, Pharm.M., Marie Y. Detrait, MD, Helene Labussiere-Wallet, MD, Sandrine Hayette, PhD, Isabelle Tigaud, MD, Mohamed Elhamri, PhD, Lila Gilis, MD, Laure L Lebras, MD, Fiorenza Barraco, MD, Sophie Ducastelle, MD, Valentina Bozzoli, MD, Franck E. Nicolini, MD PhD, Xavier Thomas, MD PhD

Blood (2014) 124 (21): 3892.

https://doi.org/10.1182/blood.V124.21.3892.3892

Published: 2014

Journal Articles

TET2 Exon 2 Skipping Confers Sensitivity to AraC and Is an Independent Favorable Prognostic Factor in AML Patients Treated with Intensive Chemotherapy

Blood (2014) 124 (21): 68.

https://doi.org/10.1182/blood.V124.21.68.68

Published: 2014

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation for Therapy-Related Acute Myeloid Leukemia

Mauricette Michallet, MD PhD, Mohamad Sobh, Pharm.M., Jeremy Monfray, CRA, Hélène Labussière-Wallet, MD, Sandrine Hayette, PhD, Isabelle Tigaud, MD, Mohamed Elhamri, PhD, Lila Gilis, MD, Laure L Lebras, MD, Fiorenza Barraco, MD, Sophie Ducastelle, MD, Valerie Dubois, Franck E. Nicolini, MD PhD, Xavier Thomas, MD PhD

Blood (2014) 124 (21): 2542.

https://doi.org/10.1182/blood.V124.21.2542.2542

Published: 2014

Journal Articles

Skipping of ATP-Binding Cassette Transporter A3 Exon 19 in AML Cells Is an Independent Prognostic Factor in Patients with Normal Cytogenetics

Blood (2014) 124 (21): 2324.

https://doi.org/10.1182/blood.V124.21.2324.2324

Published: 2014

Journal Articles

Therapeutic Management of Acute Myeloid Leukemia Patients after Stratification on Age, Prognosis and Allogeneic Hematopoietic Stem Cell Transplantation Eligibility

Mauricette Michallet, MD PhD, Mohamad Sobh, Pharm.M., Mohamed Elhamri, PhD, Jeremy Monfray, CRA, Helene Labussiere-Wallet, MD, Sandrine Hayette, PhD, Isabelle Tigaud, MD, Lila Gilis, MD, Laure L Lebras, MD, Fiorenza Barraco, MD, Sophie Ducastelle, MD, Adriana Plesa, MD, Valerie Dubois, Franck E. Nicolini, MD PhD, Xavier Thomas, MD PhD

Blood (2014) 124 (21): 3691.

https://doi.org/10.1182/blood.V124.21.3691.3691

Published: 2014

Journal Articles

Cryptic XPO1-MLLT10 translocation is associated with HOXA locus deregulation in T-ALL

Jonathan Bond, Aurélie Bergon, Amandine Durand, Isabelle Tigaud, Xavier Thomas, Vahid Asnafi, Salvatore Spicuglia, Elizabeth Macintyre

Blood (2014) 124 (19): 3023–3025.

https://doi.org/10.1182/blood-2014-04-567636

Published: 2014

NARROW

T rial of Imatinib after Ponatinib Induction (TIPI) in the Front-Line Treatment of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Setting. Report of the First Therapeutic Sequence

Therapy-Related Acute Myeloid Leukemia (t-AML) and the Advantage of Intensive Chemotherapy: Real-Life Analysis from Two Regional French Centers

Characteristics and Outcomes of Therapy-Related Acute Myeloid Leukemia: Results of Retrospective Analysis of 116 Adult Patients

Stemness Signature in AML: GEP with 17 Genes Score Versus Leukemic Stem Cell (LSC) Quantification By Multiparameter Flow Cytometry (MFC)

CP-CML Seems Related to Specific HLA Subtypes and the HLA DRB1 07 Allele Might Identify a Subgroup of Newly Diagnosed CP-CML Patients on Imatinib First-Line of Better Prognosis

Deep Molecular Response in Imatinib First-Line 418 Newly Diagnosed CP CML Patients.

Validation of the prognostic value of the knowledge bank approach to determine AML prognosis in real life

B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) with t(5;14)(q31;q32)/ IL3-IGH Rearrangement and Eosinophilia: A Peculiar IGH BCP-ALL

Impact of Body Mass Index on Outcome in Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with Imatinib in First-Line

Impact of cytogenetic abnormalities in adults with Ph-negative B-cell precursor acute lymphoblastic leukemia

Comprehensive analysis of a myeloperoxidase-negative acute promyelocytic leukemia

Very Long-Term Follow-up (> 80 months) of Imatinib (IM) First-Line for Chronic Phase (CP) CML Patients

Value of Cytogenetic Abnormalities in Adult Patients with Philadelphia Chromosome (Ph)-Negative Acute Lymphoblastic Leukemia (ALL) Treated in the Pediatric-Inspired Trials from the Group for Research on Adult ALL (GRAALL)

Flamsa Sequential Chemotherapy Followed By Reduced Intensity Conditioning and Allogeneic Hematopoietic Transplantation for High Risk Acute Myeloid Leukemia Patients

TET2 Exon 2 Skipping Confers Sensitivity to AraC and Is an Independent Favorable Prognostic Factor in AML Patients Treated with Intensive Chemotherapy

Allogeneic Hematopoietic Stem Cell Transplantation for Therapy-Related Acute Myeloid Leukemia

Skipping of ATP-Binding Cassette Transporter A3 Exon 19 in AML Cells Is an Independent Prognostic Factor in Patients with Normal Cytogenetics

Therapeutic Management of Acute Myeloid Leukemia Patients after Stratification on Age, Prognosis and Allogeneic Hematopoietic Stem Cell Transplantation Eligibility

Cryptic XPO1-MLLT10 translocation is associated with HOXA locus deregulation in T-ALL

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only